Edge Therapeutics

Screen of Nasdaq stock tickers
Biotech

Edge plans job cuts as phase 3 brain-bleed fail routs stock

A data committee found Edge’s drug was unlikely to better standard of care, prompting the biotech to stop the trial and prepare to lay off staff.
Nick Paul Taylor Mar 28, 2018 8:35am
Starting line

Edge a step closer to hemorrhage drug approval after FDA fast-track

May 13, 2016 7:42am